廣州基金國際(01367.HK):正物色優質收購目標 未達成任何協議
廣州基金國際(01367.HK)表示,雖然股份暫停買賣,但仍正在進行其日常營運,將繼續不時檢討其現有業務,並致力改善其業務營運及財務狀況。
公司表示,截至目前會繼續在境內外市場中尋找優質標的資產,先後與多個目標公司就收購方案進行磋商,但截至目前並未達成任何就收購的意向協議;亦將繼續物色擁有良好潛力及前景的公司或項目,以擴大集團業務,按照聯交所滿意之方式全面遵守上市規則,尋求儘快恢復股份買賣。
根據聯交所復牌指引,18個月期限將於2022年8月7日屆滿。股份自2021年2月8日起暫停買賣,並將繼續暫停買賣直至刊發進一步通告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.